INTRODUCTION
Infection with human immunodeficiency virus type 1 (HIV-1) often leads to neurological disease (1) (2) (3) . Disease can occur in the absence of opportunistic infection, suggesting that the virus itself and/or host response is the causative agent (1) (2) (3) . Clinical manifestations of HIV infection of the central nervous system (CNS) include deficits in cognition, behavior, and movement which collectively are referred to as the HIV-associated cognitive/motor complex; approximately 20-30% of acquired immunodeficiency syndrome (AIDS) patients develop a severe form of cognitive disorder which is also known as the AIDS dementia complex (ADC) (1) (2) (3) . Although HIV encephalitis is frequently associated with ADC, there is no 28 Molecular Medicine, Volume 2, Number 1, January 1996 clear correlation between the development of ADC or any other neurological impairment and the severity of neuropathology (1) (2) (3) . Moreover, while viral infection of the brain occurs, there is no clear link between viral load in the brain and neuropathology (1) (2) (3) (4) . Experimental infection of SIV into rhesus monkeys results in an acquired immunodeficiency syndrome that closely parallels AIDS in HIV-1-infected humans (5) . Lymphadenopathy, opportunistic infections, and a wasting disease are common clinical characteristics of SIV-infected rhesus monkeys and HIV-1-infected humans (4, 5) . Furthermore, monkeys infected with SIV can develop CNS disease similar to HIV-1-associated neurologic disease in humans (6, 7) . Currently, the SIV/rhesus monkey model represents one of the best animal models available in which to study CNS disease in HIV-1-infected humans (4, 8) .
We are interested in defining factors that contribute to CNS disease in monkeys experimentally infected with SIV. Within the brain, HIV and SIV predominantly infect macrophage and microglia (9) (10) (11) (12) (13) . Recent studies indicate that virally infected cells release a variety of factors including viral products such as gpl20 (14, 15) , and host factors such as cytokines (16) (17) (18) , arachidonic acid metabolites (16) , and quinolinic acid (19, 20) that could contribute to CNS disease. Another factor that is a potent neurotoxin is nitric oxide (NO), a short-lived radical generated through the action of nitric oxide synthase (NOS) which converts L-arginine to L-citrulline (15, (21) (22) (23) . In vivo and in vitro, NO decomposes to the stable products nitrite (NO2-) and nitrate (NO3-) (21) . Due to the short halflife of NO (on the order of seconds), NO2-and N03-are often measured as an index for total NO production (21) . Three isoforms of NOS have been identified in humans. Both neuronal constitutive NOS (ncNOS type I) and endothelial constitutive NOS (ecNOS type III) require calcium and calmodulin for activity (22) . These enzymes consitutively produce low levels of NO that regulate everyday processes such as blood pressure, peristalsis, and neurotransmission (22) .
The inducible form of NOS (iNOS type II) does not require calcium for activity (22) . A variety of human cell types such as monocyte/ macrophage, astrocytes, and hepatocytes express iNOS. Transcription for this gene can be experimentally initiated following treatment with lipopolysaccharide (LPS) and cytokines such as interferon-y (IFNy), tumor necrosis factor a (TNFa), and interleukin 1(3 (IL-113). iNOS activity produces high levels of NO thought to be important for host defense against tumor cells and wide variety of infectious agents including bacteria, fungi, and viruses (24) . Conversely, high levels of NO can result in cell death and tissue destruction (22, 24) . Potential sites of action of NO on target cells include inhibition of enzymes containing Fe-S groups (25) , disruption of signal transduction (22) , and induction of apoptosis (26) . One other potential toxic property of NO is its ability to react with superoxide anion (02-) to form peroxynitrite, which is directly cytotoxic to cells by causing lipid peroxidation and protein tyrosine nitration (27, 28) .
Recently, attention has been drawn to the role of iNOS and NO as contributing factors in a variety of human CNS diseases, including HIV-1-associated neurologic disease (29) (30) (31) . In (32), while monkey 262 was infected with a separate microglial-associated SIV stock. Monkey 188 was infected intravenously with the uncloned SIVmac251 stock of virus. All animals were monitored for the development of AIDS-associated illness at which time they were sacrificed. Histopathological examination of the brains of monkeys 185 and 188 revealed neuropathology characteristic of SIV encephalitis, whereas monkey 262 had scattered macrophages and T cells in the brain. SIV sequences could be polymerase chain reaction-amplified from DNA prepared from microglia purified from these animals.
Cell Culture Monkeys were euthanized by lethal anesthesia, followed by intracardial perfusion with sterile phosphate-buffered saline (PBS). Microglia were obtained according to previously described methods (32) . A total of five million cells were seeded into 15 X 60 mm culture dishes in a volume of 2 ml. Cells were cultured in macrophage-serum free medium (M-SFM) (Gibco/ BRL, Grand Island, NY, U.S.A.) supplemented with 10% Mac-Stim (MS) solution (Collaborative Biomedical Products, Bedford, MA, U.S.A.), which is enriched with macrophage colonystimulating factor and granulocyte/macrophage colony-stimulating factor, for 5 days in a humidified 37°C, 6% CO2 cell incubator. At the completion of the incubation period, the cells were gently washed with pre-warmed (37°C) Hanks' balanced salt solution (HBSS) to remove nonadherent cells. This resulted in a confluent monolayer of cells, of which >95% were microglia, as determined by uptake of fluorescently labeled acetylated low-density lipoprotein (Dil-Ac-LDL) (Biomedical Technologies Inc., Stoughton, MA, U.S.A.) (32) . Fresh medium was added to the monolayers every 3 days.
CSF N02-/NO3-Measurement Serial CSF samples were collected from SIV-infected monkeys (185 and 262) by tapping the cisterna magna. Only blood-free CSF were used for NO27/NO3-analysis by the protocol from the Cayman Nitrite/Nirate Assay Kit (Alexis Corporation, San Diego, CA, U.S.A.). Briefly, the reaction is a two-step process with the first step converting N03 to NO2-using nitrate reductase and the second step utilizing the Griess reagents to chemically convert N02 into an azo compound. Total NO2/NOf3 compounds are then determined by spectrophotometric absorbance at 540 nm.
p27 Antigen Measurement Plasma and CSF samples were collected from monkeys (185 and 262) and stored at -700C until analyzed. SIV p27 antigen was measured using a commercial SIV p27 antigen capture enzyme-linked immunosorbent assay (ELISA) kit according to manufacturers specifications (Coulter Corporation, Hialeah, FL, U.S.A.).
Reverse Transcriptase-Polymerase Chain Reaction Analysis Microglia from monkey 262 were cultured with or without LPS (100 ng/ml) for 24 hr at which time total cellular RNA was prepared by guanidinium thiocyanate/phenol/chloroform extraction (33) . cDNA from each cell population was prepared with 1 ,ug of RNA as template using Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI, U.S.A.) and random hexamer nucleotide primers (Promega) (33) . Fifty microliters total volume of cDNA was prepared, of which 4 ,ul was polymerase chain reaction (PCR) amplified in 50 ,ul reaction containing 1.5 mM MgCl2, 0.2 mM each of the four deoxynucleotide triphosphates, 0.5 U of Taq polymerase, and 0.7 ,uM each of primers specific for human iNOS and mouse L32. The iNOS primers correspond to nucleotides 212-232 (CTG TCC TTG GAA ATT TCT GTT) and 699-680 (TGG CCA GAT GTT CCT CTA TT) of the human hepatocyte iNOS. The mouse L32 primers were as follows: 5'-GTG GGG CCC AAG ATC GTC AAA AAG-3' and 5'-CAG TAC GTA AGA TT T GTT GCA CAT-3'. RNA which increased as the animal became ill (Fig. 1A) . Plasma NO2U/NO3 levels from this monkey were higher than CSF NO2-/NO3-levels prior to infection (Fig. IB) . Plasma NO2/ NO3-levels declined following infection and plateaued until the animal became ill, at which point NO2/NO3 levels increased.
In contrast to the findings in the CSF, plasma viral p27 antigen from monkey 185 spiked at Day 14 postinfection, rapidly decreased, then gradually rose again during the course of infection (Fig. iB) and plasma NO2 /NO3 production. Furthermore, NO27/NO3 anions are not thought to pass freely through the blood-brain barrier (37) . Finally, only CSF samples free of blood were used for NO2-/ NO3-measurement, so it is unlikely that contaminating NO-producing PBMC were present within the CSF. Thus, these data suggest that the presence of NO2 /NO3 in the CSF of these monkeys reflects local NO production within the CNS.
Detection of iNOS, IFNy, and IL-l1, by in Situ Hybridization
In situ hybridization was used to detect expression of iNOS mRNA in postmortem brain tissue from SIV-infected monkeys. mRNA for iNOS was found in the cerebral cortex of a monkey (188) with SIV-encephalitis as well as a monkey that did not display encephalitis at autopsy (monkey 262) (Fig. 2 A and B detected from LPS-treated microglia whereas no product was detected from untreated microglia (Fig. 3) . Sequence analysis of the PCR product revealed greater than 95 % nucleotide and amino acid similarity to human hepatic iNOS (Fig. 4) . There was no significant similarity to human ncNOS or ecNOS. It is unlikely that contaminating PBMC were responsible for iNOS production as the brain was perfused extensively prior to isolation of microglia. These results demonstrate that SIV-infected microglia can produce iNOS mRNA following stimulation with LPS.
DISCUSSION
The production of NO with lymphocytic choriomeningitis virus (LCMV) (43) and borna virus (44) expressed iNOS in the brain which coincided with the development of neuropathology. In humans, iNOS has been indirectly identified by NADPH diaphorase staining in regions of demylination in patients suffering from multiple sclerosis (MS), suggesting a role for NO in the pathogenesis of MS lesions (29) . Recently, expression of iNOS has been speculated to have a role in HIV-1-induced neuropathology (1, 15, 31) . In support of this, iNOS mRNA has been detected by RT-PCR in postmortem brain tissue of a child with advanced HIV encephalitis (30) . We have demonstrated that an increase in NO2 /NO3 levels is observed in the CSF of monkeys with SIV-induced CNS disease. iNOS, IFNy, and IL-1(3 mRNA were all observed in the brains of SIV-infected monkeys by in situ hybridization. Furthermore, LPS-stimulated microglia from an SIV-infected monkey produce iNOS mRNA. These data suggest that iNOS and, more specifically, NO is expressed in the brains of SIV-infected monkeys and potentially contributes to SIV-induced CNS disease.
The increased levels of NO2 /NO3f in serial CSF samples from SIV-infected monkeys suggest that NO is produced locally within the CNS. A recent study has reported that no significant increase in average CSF levels of NO2U/NO3 were observed in HIV-infected patients (37) . However, significant levels of NO2 /NO3-have been reported to be present in the CSF of patients with either bacterial or viral meningitis, suggesting that NO may play a role in the pathogenesis of this disease (36, 37) . A sharp increase in NO2/ NO3-levels in the CSF of monkey 185 was observed 7 days following infection. Whether this was in response to viral infection of the CNS is unclear, as only low levels of SIV p27 protein were present at this time. However, SIV is able to infect the CNS of rhesus monkeys very early following infection (45) , thus the increased NO2 /NO3 levels may reflect a response to early viral infection of the brain. In support of this, Bukrinsky et al. (30) have shown that HIVinfected human macrophages produced peak amounts of NO between 5 and 7 days postinfection. The time frame of these observations somewhat parallel the kinetics of NO2-/NO3-production and would support early viral entry into the CNS.
We have demonstrated iNOS mRNA in the brains of monkeys infected with SIV by in situ hybridization. However, the identity of the cell type(s) responsible for iNOS expression in brain tissue from SIV-infected monkeys is not known. Monocyte/macrophage have been shown to be the primary cell type responsible for iNOS production in the brains of rats infected with borna disease virus and mice infected with LCMV (43, 44) . Human fetal astrocytes can be stimulated for iNOS production following treatment with IFNy and IL-1l3 (40) . In fact, astrocytes were thought to be responsible for production of iNOS in demyelinating lesions of MS patients (29) . Thus, it is entirely possible that cells other than microglia are responsible for iNOS expression in the brain of SIV-infected monkeys.
The cytokines IFNy and IL-1i, alone or in combination with other factors, have been shown to contribute to the stimulation of cultured human monocyte/macrophage and astrocytes to produce iNOS (40, 41 (24, 46) . Considerable evidence now exists that human monocyte/macrophage can be stimulated to produce iNOS (30, 42) . However, human microglia do not appear to be efficient in iNOS production following exposure to IFNy and LPS (47) . HIV-1-infected human monocyte/macrophages have been shown to produce iNOS and NO following LPS and TNFa stimulation (30) . Human hepatocytes, as well as human lung epithelial cells, require exposure to a combination of factors which include IFNy, TNFa, IL-13, and LPS in order to be stimulated to produce iNOS (38, 39) . We have shown that microglia obtained from an SIV-infected monkey can be stimulated with LPS to produce iNOS, whereas unstimulated microglia do not express iNOS. The effects of other factors such as IFNy, IL-1,3, or TNFa on microglial iNOS production have not been yet been examined, and this would be of great interest in light of our observations that IFNy and IL-113 are produced in the brain during SIV infection.
High levels of NO may alter normal cell function by inhibiting enzyme function, inducing apoptosis (26) , or disrupting signals for neurotransmission (22) . NO has also been shown to damage and kill cultured neurons (15) . We have also determined that microglia from SIV-infected monkeys produce superoxide anion (02-) (data not shown). NO reacts with 02-to form the peroxynitrite anion, which is relatively stable at physiological pH, thus enabling this molecule to diffuse over a wide tissue area (27) . Cellular targets for peroxynitrite include lipid peroxidation, which is directly toxic to cells and nitration of tyrosine residues which can disrupt signal transduction (27, 28) . Thus, in addition to having a direct toxic effect on cells, NO may indirectly mediate a variety of other potentially neuropathogenic mechanisms.
In addition to inducing iNOS, IFN'y may activate cells of the CNS to produce other neurotoxic factors including TNFa, IL-2, and TGFJ3, prostaglandins, and arachidonic acid metabolites (16, 17) . Expression of IFNy may also influence viral load in the brain of SIV-infected monkeys (48) . Elevated levels of have been observed in the brains of patients with HIV-1-induced CNS disease (17, 49) . Increased levels of IL-113 have been shown to kill oligodendrocytes and destroy myelin (17) . Furthermore, IL-If3 has been shown to induce expression of other cytokines such as TNFa and IL-6, as well as enhance HIV-1 replication (17) . Although the source of IFN,y has not been investigated, we have previously identified the presence of CD8+-cytotoxic T lymphocytes in the brains of SIV-infected monkeys with SIV-encephalitis (50) . These cells represent a potential source of IFNy.
The demonstration that iNOS and NO2/ N03-are produced during the course of SIV infection of the CNS suggests that NO could potentially be contributing to SIV-induced CNS disease. However, NO is but one of many host factors produced that could lead to neurologic disease. Further work with the SIV/rhesus monkey model may provide valuable insight into identifying key events in the pathology leading to HIV-l-associated CNS disease and ADC.
